BEVERLY, MA and TORONTO--(Marketwire - June 08, 2012) -
Hamilton Thorne Ltd. (TSX VENTURE: HTL
) ("Hamilton Thorne" or the "Company"), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced the Company's Annual General and Special Meeting ("AGM") will be held on Tuesday, June 12, 2012. The Management Information Circular and 2011 Annual Report, and all relating financial year-ended December 31, 2011 information, have been posted to shareholders and are available for download on the Company's Website http://www.hamiltonthorne.com/
The AGM will take place at the offices of Hamilton Thorne, located at 100 Cummings Center, Suite 465 E in Beverly, MA at 10:00 a.m.
The Company also announced that it has extended the closing deadline for its non-brokered private placement (the "Offering") of units (each, a "Unit") of the Company, announced on April 23, 2012, to July 7, 2012 (the "Closing Deadline"). Each Unit has an offering price of $0.1125 per Unit (the "Offering Price") and is comprised of one common share (each a "Common Share") and one half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire an additional Common Share at an exercise of $0.16875 per Common Share for a period of twelve months following the closing.
On May 16, 2012, the Company completed the first tranche of the Offering, issuing an aggregate of 4,006,668 Units at the Offering Price for aggregate gross proceeds of approximately US$450,000. The Company may continue to accept additional subscriptions for up to approximately US$300,000 (approximately 2,660,000 Units) until on, or about, the Closing Deadline.
For further details on the Offering, please refer to the Company's press releases dated April 23, 2012 and May 16, 2012, respectively, copies of which are available at www.sedar.com.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced image analysis systems for the fertility, stem cell and development biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its image analysis systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses.
Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.